Press Releases

Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020.

Roswell Park’s Francisco J. Hernandez-Ilizaliturri, MD, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Dr. Hernandez-Ilizaliturri is presenting the team’s findings at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

A group of researchers led by Roswell Park's Maximillian Merz, MD, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma and is presenting the findings at ASH 2020.

Eunice Wang, MD, is leading multiple research efforts focused on different treatment approaches for acute myeloid leukemia (AML) patients. During the ASH Annual Meeting and Exposition, she is presenting data on two ongoing studies incorporating new treatment options.

Research and insights from the Roswell Park team will help to fuel three important research meetings in the week ahead as researchers in oncology, hematology and immunotherapy come together virtually for the Immunotherapy Bridge 2020 meeting, Melanoma Bridge 2020 meeting and 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Continuing to reach across international borders, Roswell Park’s Department of Indigenous Cancer Health has launched a number of educational and communications initiatives.

Roswell Park Comprehensive Cancer Center is among 100 of the nation’s top health care systems, representing thousands of hospitals in communities across the U.S., that have come together with an urgent plea for all Americans: mask up, because wearing a facemask is our best chance at slowing the surging COVID-19 pandemic now.

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

A team led by Subhamoy Dasgupta, PhD, has determined that prostate cancer tumors change their metabolism to produce more fats, which helps them spread to and survive within the bones.